Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

This Award Notice opportunity from United States Department of Agriculture was posted on September 26, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Broad-Spectrum Antivirals for Honey Bees in Crisis

Awarded
220185SBIR / STTR

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.
W6QK Acc-Apg

POSTED

1 day ago

DEADLINE

N/A
NAICS: 541714
New
Federal
DNA Sequencing Service
Solicitation # 75N98027Q00090
The National Institutes of Health (NIH) is soliciting a Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract for high-throughput DNA sequencing services, including Sanger DNA sequencing and whole-plasmid sequencing. The scope of work involves processing plasmid DNA, genomic DNA, and PCR-generated material, with requirements for PCR amplification, product purification, and DNA normalization. The contractor is responsible for providing all sample collection and shipping materials, maintaining strict confidentiality of sequencing data, and retaining DNA samples for at least 180 days post-sequencing. Deliverables include specific electronic file formats such as .ab1, .fasta, and raw FASTQ data, alongside a Monthly Status Report submitted to the Contracting Officer's Representative (COR). The contract spans a five-year period from January 4, 2027, to January 3, 2032, with a total estimated value ranging from $184,200.00 to $958,584.20. Performance and delivery are centered at the NIEHS facility in Research Triangle Park, North Carolina. Award selection will be based on a best value tradeoff, where technical capability and past performance are weighted more heavily than price. Technical evaluations will focus on sequencing capability, personnel qualifications, quality assurance/control, and data management. The acquisition is not set aside for small businesses and falls under NAICS code 541714.
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 19 days
NAICS: 541714
New
Federal
FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Solicitation # FDABAA-27-00123
The FY27 FDA Broad Agency Announcement (FDABAA-27-00123) is a solicitation by the Department of Health and Human Services, Food and Drug Administration (FDA), for basic and applied research and development proposals to support regulatory science and innovation. The BAA identifies 22 priority research areas, including updated interests in nonclinical development such as human tooth enamel evaluation techniques. Per Executive Order 14434, the agency has transitioned the terminology from Artificial Intelligence to Super Intelligence within the tobacco and nicotine research section. The solicitation is open to all responsible sources, including academic institutions and small businesses, with awards issued via procurement contracts. Proposals must follow a two-tiered submission process consisting of a checklist, a three-page concept paper, and a full technical proposal, all submitted as a single PDF not exceeding 2 megabytes. The deadline for these submissions is January 22, 2027. Evaluation is based on a peer-review process focusing on innovation, technical soundness, scope understanding, and the significance of the problem addressed. Successful offerors must adhere to Good Manufacturing Practice Regulations and provide monthly technical progress reports. All applicants are required to maintain active SAM.gov registration and disclose any potential organizational conflicts of interest.
FDA Office Of Acq Grant Svcs

POSTED

1 day ago

DEADLINE

in 2 months
NAICS: 541714
New
Federal
Presolicitation Notice to Sole Source for Experimental Pathology Laboratories, Inc. (EPL)
Solicitation # Presolicitation_NOI_Sole_Source_EPL
The U.S. Environmental Protection Agency, through the Office of the Chief Procurement Officer's Water, Tribal, and Science Division, intends to award a firm-fixed price purchase order for histology and pathology services of maternal and neonatal rodent specimen organs. The work will be performed at the EPA Headquarters in Washington, DC, and focuses on the toxicologic pathology of environmental contaminants, including PFAS, phthalates, air pollutants, and endocrine-disrupting compounds. This acquisition is intended to continue existing larger studies to maintain data integrity and avoid protocol deviations. The EPA intends to sole source this requirement to Experimental Pathology Laboratories, Inc. (EPL) due to their specialized experience with environmental contaminants, compliance with Good Laboratory Practice regulations, and their ability to accept hand-delivered samples as a local vendor. The procurement falls under NAICS code 541714 for Research and Development in Biotechnology and PSC code AZ11. While the agency intends to award to EPL, other responsible sources may submit capability statements, proposals, or quotations by November 30, 2026. The estimated award date is December 3, 2026. All vendors must maintain a public profile in the System for Award Management and utilize the FedConnect portal for contract communications.
Tribal & Science Division Water

POSTED

5 days ago

DEADLINE

in 12 days

AI Contract Overview

Show more

The United States Department of Agriculture has awarded a Phase I contract to ELIXIDE to develop broad-spectrum antivirals to combat honey bee colony collapse, specifically targeting the Deformed Wing Virus. Addressing a significant economic burden and threat to food security, the project focuses on inhibiting RNA-dependent RNA polymerase, a protein essential for viral reproduction that is absent in honey bees and mammals. Using a validated three-dimensional model created via ColabFold, the initiative will employ the SilcsBio and OpenVS platforms to identify and test the safety and effectiveness of hit molecules. The project is structured in two phases, with Phase I focusing on the identification of inhibitors and Phase II dedicated to refining drug-like properties and conducting colony-level effectiveness tests. Given the substantial global honey bee medicine market and the potential for these antivirals to be applied across various veterinary and agricultural sectors, the project anticipates significant revenue growth. This effort aims to stabilize pollinator populations and protect essential crop ecosystems from the devastating impact of RNA viruses.

General Info

USDA awarded ELIXIDE a contract to develop antivirals combating honey bee colony collapse.

Documents

0

No documents available

This contract was awarded without public documents.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

This one is closed. Find the next one like it.

Open contracts like this one, right now:

  • DNA Assay Development and Optimization SupportOpen now, due in 19 days
  • Whole-Plasmid Sequencing and Bioinformatics AssemblyOpen now, due in 19 days
See open contracts like this

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhaseAwarded
Posted

Award Notice

Awarded

Contract was awarded

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyUnited States Department of Agriculture
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
In 2023, domestic beekeepers lost an estimated 48% of their colonies, higher than the average loss rate of 39.6%, since 2010. Colony losses threaten food safety and present a $250 million annual economic burden for commercial beekeepers. Therefore, there is an urgent need to ensure the safety of pollinators, which are essential for crop protection and ecosystem stability.RNA viruses, in particular Deformed Wing Virus, are a primary cause of honey bee mortality. RNA-dependent RNA polymerase (RdRp) controls the reproductionof all RNA viruses and does not exist in honey bee and mammalian cells. Therefore, it is a safe therapeutic target for developing broad-spectrum antivirals.Since no experimental structure is available for DWV RdRp, ELIXIDE built a new three-dimensional validated model using ColabFold. ColabFold internalizes the machine-learning approach and parameters used in AlphaFold. In Phase I, we aim to identify RdRp inhibitors of DWV using two independent state-of-the-art drug discovery platforms: 1) SilcsBio and 2) the artificial intelligence-accelerated platform OpenVS with the RosettaVS protocol. The safety and effectiveness of the hit molecules will be tested on honey bees. In Phase II, we will improve the drug-like properties of the leads and test their effectiveness at the colony level.The honey bee medicine market is valued around $135M in the US and $5B worldwide. As we aim to identify a broad-spectrum antiviral medication, we expect exponential revenue growth from the drug's broad applications in other veterinary and agricultural practices.

Get AI-powered intelligence on the opportunities still open

Every solicitation package arrives shredded into a compliance breakdown and matched to your past performance, with incumbent history and alerts on amendments and award.

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS